NewGen IVF Prices $1.25 Million Offering at $0.07 Per Share; NIVF Falls 38%

NewGen IVF Group Ltd. (NIVF) priced a public offering expected to raise approximately $1.25 million in gross proceeds, sending its stock down 38.44% to close at $0.34 on September 28, 2026. The offering comprises 17.85 million common shares, or pre-funded warrants in lieu thereof, at $0.07 per share or $0.06999 per pre-funded warrant. The pre-funded warrants are immediately exercisable until exercised in full. Aegis Capital Corp. is the exclusive placement agent, with the transaction expected to close on or about September 30, 2026. NewGen IVF, which provides digital asset management and reproductive health solutions, intends to use the proceeds with existing cash to invest in K25.ai, restructure debt, manufacture and deploy Nodexus cell-sorting machines, and fund working capital and general corporate purposes. The shares have traded between $0.3196 and $1,539.00 over the past year. In overnight trading, NIVF fell 19.61% to $0.27.